Airsupradupra

Quote




anonymous said:
Any layoffs or restructuring?
Click to expand...
Don't know but there should be within brand and managed markets. For a "revolutionary" drug, the MCO's certainly aren't aligning to that horse manure. Q3 goals are looking silly as the nation is sitting at around 80%. Heard that Q4 goals will be much sillier. These Einstein's must think providers will use the co-pay cards ad infinitum. A little tidbit...They won't.
Can see it now as we enter Q1 25', the hoopla for getting on a couple of small Part D plans will be comical.
SilverScript, UHC/AARP, Aetna, Humana, WellCare. The must haves.
 




Well, the Q3 goal crap has caused me to stop selling it. 100% Breztri moving forward. Data capture is a joke. Heard Q4 will be crazy as well, so ya wanna play those games? OK, I'll just put calls in and play along.
 




Continued silence on the managed care front. I guess the big plans don't think two generic drugs in one device is a revolutionary as the brand team thinks. Maybe the Acct Directors can do some web-exs and programs with their customers. That should be just the impetus the brand needs to drive usage. LOL
 








Wasn't it awesome that we got a box of stuff from the brand team delivered to our homes that were already on the eStore available for ordering? I would bet many of us already had adequate supplies of what we wanted/needed. Anyway, most of the stuff I received went right in the trash. Desperation? IDK but an argument could be made.
 




anonymous said:
Wasn't it awesome that we got a box of stuff from the brand team delivered to our homes that were already on the eStore available for ordering? I would bet many of us already had adequate supplies of what we wanted/needed. Anyway, most of the stuff I received went right in the trash. Desperation? IDK but an argument could be made.
Click to expand...
Same here and they overnighted me the box. Straight to the dumpster. Waste of money. Bunch of morons
 




anonymous said:
Same here and they overnighted me the box. Straight to the dumpster. Waste of money. Bunch of morons
Click to expand...
Good move. AZ management exists in a glass house unwilling to see reality and human suffering. Combining two generic drugs and charging what AZ is charging is criminal, as if albuterol and budesonide are new inventions. Quit being so SELFISH AZ and HELP your asthmatics. Currently you are not. You would sell a lot more @ $35 way above your cost of development! Quit gouging!
 




anonymous said:
I just laugh at the stupid posts from our "sales" reps. We should rename them to lunch caterers. My middle school child can do the job!
Click to expand...
I would hope you care enough about your child not to steer them in this direction- industry wise. Access has changed drastically, metrics put good people in a position where their best efforts wouldn’t hit the mark. And everyone is replaceable at any moment (including yourself) I read through this thread and all I see are frustrated employees sharing obstacles they encounter in the positions they hold- for what seem to be completely valid reasons. If this hit you on an emotional level you’re already doing it wrong, you work for the company- why are you so emotionally invested? You sound suspiciously like a sales manager in industry, nothing personal- but this a position that has been irrelevant in the industry for….. ever actually.

That question indeed, in case it wasn’t clear, was rhetorical. I don’t know if my brain cells can survive another one of your epiphanies.
 




If you haven't seen or heard yet, the CMS has shared what drugs will be $2 next year for Medicare patients. One of them is albuterol. Not a good thing for Airsupradupra. Now we know the brand will say, our targets are commercially insured patients. Easy out. Asthma affects many over the age of 65 and since pulmonary patients are predominantly over 65, the fact that patients can pay $2 for a generic or (if lucky) $50 if Airsupra is preferred on a Med D a particular patient's formulary, I don't see us capturing much of the biz.
Managed Markets better start expanding preferred access on other commercial plans. State level BSBS's would be a big +.
 








Goals are ridiculous for Q4. I guess the glass half full view is AZ is consistent quarter to quarter. No new large commercial insurers coming on board and albuterol will be $2 on Med D plans. I see AZ selling Airsupra off within two years (end of 26') unless brand is more aggressive with the pricing strategy.
 
















Top Bottom
Back
Quote